Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 32

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 32
---
 into a research and licensing agreement with Ramot - the commercialization arm of Tel Aviv University, and Professor Shimon Efrat, a leading scientist in the joint research on behalf of Tel Aviv University. For the cooperation between the parties, Kadimastem must pay to Ramot royalties at a rate of 0.3%-0.8% for product sales, depending on progress according to the product's regulatory milestones and the degree of use of Ramot’s technology developed during the project, as stipulated in the agreement. In addition, royalties will be paid to Ramot at a rate of 2.75% for consideration received by Kadimastem for sublicensing of product in the field of diabetes, depending on the milestone specified in the agreement; or royalties at the rate of 7% if the sublicensing is for a product that combines the technology of Ramot. It was also agreed that Kadimastem would grant to Ramot up to 200,000 options, free of charge, subject to reaching regulatory milestones, at the following rates: 30% of the options would be granted after meeting with a regulatory body, prior to submitting the IND application; additional options will be granted after the submission of the IND application; and an additional 40% of options will be granted after receiving the IND approval. The granting of such options is subject to Professor Efrat continuing to advise Kadimastem throughout various stages of the product's regulatory approval. Intellectual Property Kadimastem seek and have obtained some patent protection as well as other effective intellectual property rights for Kadimastem’s products and technologies in the United States and internationally. Kadimastem’s policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of Kadimastem’s business. A list of each of Kadimastem’s patent families, including each of their status, their filing locations, and application information, is set forth below: METHODS OF GENERATING GLIAL AND NEURONAL CELLS

| Kadimastem’s   
 Ref Client Ref |     | Country   |     | Earliest                 
 Priority                 |     | Entry       
 Date        |     | Filing                 
 Date Application No.   |     | Publication                             
 Date + No. Issue Date + Patent No.      |     | Next                 
 Action               |     | Status  |     | Assignee                                                           
 Inventor                                                           |
| 45463 2006-075